Sutro Biopharma
STRO
114 hedge funds and large institutions have $240M invested in Sutro Biopharma in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 43 increasing their positions, 29 reducing their positions, and 15 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 29
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
40% more call options, than puts
Call options by funds: $7K | Put options by funds: $5K
23% more capital invested
Capital invested by funds: $194M → $240M (+$45.4M)
6% more funds holding
Funds holding: 108 → 114 (+6)
0.07% less ownership
Funds ownership: 9.23% → 9.17% (-0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.32M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$1.42M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$1.33M |
| 4 |
Renaissance Technologies
New York
|
+$1.12M |
| 5 |
Two Sigma Investments
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$7.4M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$5.96M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.71M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.03M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$785K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$17.2K | -495 | Closed |
|
|
CUAMC
127
China Universal Asset Management Company
Shanghai,
China
| – | -$5.37K | -155 | Closed |
|
128
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -16 | Closed |
|
129
Simplex Trading
Chicago,
Illinois
| – | +$603 | +19 | New |
|
STRO Hedge Fund Activity: Q4 2023 in Review
114 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2023, worth a combined $240M — up 23% from $194M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new STRO positions and 15 closed out — a net gain of 6 holders — while 43 added to existing stakes and 29 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.32M. The largest seller was Holocene Advisors, exiting entirely with an estimated $7.4M sold.
- 114 institutional investors held Sutro Biopharma (STRO) as of Q4 2023, up from 108 in Q3 2023.
- Funds reported $240M of Sutro Biopharma stock for Q4 2023, up 23% quarter-over-quarter.
- 21 funds opened new Sutro Biopharma positions in Q4 2023 and 15 closed out, a net change of +6 holders.
- The largest Sutro Biopharma buyer in Q4 2023 was Adage Capital Partners, an estimated $4.32M added.
- The largest Sutro Biopharma seller in Q4 2023 was Holocene Advisors, an estimated $7.4M sold.
Based on aggregated 13F filings for Q4 2023.